Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in the News.
Press releases published on April 28, 2025
Green Thumb to Open RISE Dispensary Ocala in Florida, its 104th Retail Location in the Nation, on April 29
GlobeNewswire
·
April 28, 2025
CHICAGO and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- RISE Dispensaries, a rapidly growing cannabis retail chain owned by Green Thumb Industries Inc. (“Green Thumb” or the “Company”) (CSE: GTII) (OTCQX: GTBIF), today announced that …
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
GlobeNewswire
·
April 28, 2025
VYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare professional PITTSBURGH, April 28, 2025 ( …
Clear Blue Technologies International to provide Corporate Update and Report Fiscal 2024 Financial Results and Host Conference Call on Thursday, May 1st, 2025
GlobeNewswire
·
April 28, 2025
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Clear Blue Technologies International Inc. (TSXV: CBLU) the Smart Off-Grid™ Company, today announces that it will provide a corporate update and also report financial results for its fiscal 2024 on Wednesday, …
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
GlobeNewswire
·
April 28, 2025
Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA’s Uniquely Efficient Internal R…
Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
GlobeNewswire
·
April 28, 2025
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients …
Osisko Development Announces Optimized Feasibility Study for Permitted Cariboo Gold Project with C$943 Million After-Tax NPV5% and 22.1% IRR at US$2,400/oz Base Case Gold Price; at US$3,300/oz Spot Gold C$2.1 Billion After-Tax NPV5% and 38.0% IRR
GlobeNewswire
·
April 28, 2025
(All dollar amounts are expressed in CAD dollars, unless stated otherwise) HIGHLIGHTS1 Robust returns with base case after-tax NPV5% of $943 million, unlevered after-tax IRR of 22.1% and payback2 of 2.8 years at $2,400/oz gold price assumption. Using spot …
Village Farms International Takes Top Honors at the 2025 Stevie® Awards
GlobeNewswire
·
April 28, 2025
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms” or the “Company”) (NASDAQ: VFF) was named the winner of two Gold Stevie® Awards and one Bronze Stevie® Award in the 23rd Annual American …
Auron Presents Preclinical Data Highlighting the Activity of AUTX-703 in Prostate Cancer at 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
NEWTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced preclinical data in prostate …
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
GlobeNewswire
·
April 28, 2025
ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs …
Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025
GlobeNewswire
·
April 28, 2025
Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both adaptive and innate anti-tumor activity In multiple …
Ocular Therapeutix™ to Report First Quarter 2025 Financial Results on May 5, 2025
GlobeNewswire
·
April 28, 2025
BEDFORD, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to issue a press release regarding first quarter …
G2 Continues to Expand New Surface Gold Discovery and Provides Exploration Update
GlobeNewswire
·
April 28, 2025
G2 drills 41m @ 1.2 g/t Au …
DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma
GlobeNewswire
·
April 28, 2025
FRIENDSWOOD, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its achievement of surpassing a significant milestone of 200,000 …
Beamr to Participate in Upcoming Investor Conferences in May 2025
GlobeNewswire
·
April 28, 2025
Beamr will present at the Ladenburg Thalmann Technology Innovation Expo in New York, and participate virtually in the Needham 1x1 Conference Herzliya, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video …
XORTX Announces Grant of European Patent
GlobeNewswire
·
April 28, 2025
CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
ScottsMiracle-Gro CEO Reports Strong POS Unit Gains During CNBC Mad Money Appearance
GlobeNewswire
·
April 28, 2025
MARYSVILLE, Ohio, April 28, 2025 (GLOBE NEWSWIRE) -- The Scotts Miracle-Gro Company (NYSE: SMG), the world’s leading marketer of branded consumer lawn and garden products as well as a leader in indoor and hydroponic growing products, reported that Chairman …
Nayax to Showcase End-to-End Payment Ecosystem at The NAMA Show, May 7-9 in Las Vegas
GlobeNewswire
·
April 28, 2025
HERZLIYA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement payments and loyalty platform designed to help merchants scale their business, will be showcasing its range of solutions at The NAMA …
Globavend Receives Government Non-Dilutive Grant Funding Approval
GlobeNewswire
·
April 28, 2025
Approval-in-Principle Received For Up To $900,000 in Government Funding to Directly Support Globavend’s Expansion into the China Market PERTH, AUSTRALIA, April 28, 2025 (GLOBE NEWSWIRE) -- Globavend Holdings Limited (Nasdaq: GVH) (the “Company” or “ …
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)
GlobeNewswire
·
April 28, 2025
- NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “ …
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
GlobeNewswire
·
April 28, 2025
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings support continued evaluation …